The NCCN recommends the use of the 4Kscore® test in the 2015 Prostate Cancer Early Detection Guidelines

cáncer de próstata

On 26 June, OPKO Health Inc. announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN guidelines for prostate cancer early detection. The panel concluded that the 4Kscore®, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy or after a negative biopsy to assist patients and physicians in further defining the probability of high-grade cancer.

“We are pleased that the NCCN, an organisation leading the way in the establishment of evidence-based guidelines for cancer diagnostics, is recommending the use of the 4Kscore® test in the 2015 Prostate Cancer Early Detection Guidelines”, said David Okrongly, PhD., President of OPKO Diagnostics.

The 4Kscore® test has been studied in over 22,000 patients with results published in 12 scientific publications. “Since its launch, I have been offering and using the 4Kscore® test with my patients who have an abnormal PSA prior to a first prostate biopsy and before repeating a prostate biopsy after a negative biopsy”, said Dr Dipen Parekh, Professor and Chair of the Department of Urology at the University of Miami and principal investigator for the recently-published United States multicentre study.“The 4Kscore® test provides me with important information about my patient’s individual risk for having aggressive prostate cancer and allows me to decide with my patient about whether or not to proceed with a prostate biopsy or safely monitor the patient.”

The 4Kscore® test is the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer. In arriving at their recommendations, the NCCN panel stated: “The challenge is to minimise immediate treatment (or over-treatment) of indolent cancers by accurately characterising the biology of the detected cancer. Identification and selective treatment of aggressive cancers should result in significant decreases in morbidity and mortality while limiting adverse effects on quality of life.”

“OPKO is committed to the strategy that effective therapy, particularly cancer therapy, can be greatly enhanced by use of diagnostic tests”, said Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer. “Through diagnostics, we can enable physicians to take a more targeted and precise approach in their treatment strategies and thus improve patient outcomes and lower overall healthcare costs.”

Leave a Comment

Your email address will not be published.